NLS Pharmaceutics to Present at the 35th Annual Roth Conference
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) announced that CEO Alex Zwyer will present at the 35th Annual Roth Conference on March 13, 2023, at 10:00 AM PT (1:00 PM ET) in Dana Point, CA.
The conference will include small group meetings, analyst-led fireside chats, and company presentations from around 400 private and public companies across various sectors.
Live audio webcasts and replays will be available in the investor relations section of the Company's website.
- None.
- None.
ZURICH, SWITZERLAND / ACCESSWIRE / March 1, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced Alex Zwyer, CEO, will be presenting at the 35th Annual Roth Conference.
Event | 35th Annual Roth Conference |
Date | March 13, 2023 |
Presentation | 10:00 AM Pacific Time (1:00 PM Eastern Time) |
Location | Dana Point, CA |
This year's event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic industry panels, and company presentations by executive management from approximately 400 private and public companies in a variety of growth sectors including: Business Services, Consumer / Health & Wellness, Healthcare, Resources: Oil & Gas / Metals & Mining, Technology, Media & AgTech and Sustainability/ESG.
To learn more and submit a registration request, visit https://ibn.fm/Roth2023Registration
The live audio webcast and replay will be available in the investor relations section of the Company's website at https://nlspharma.com/investors/events-and-presentations/
About ROTH MKM
ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com
SOURCE: NLS Pharmaceutics Ltd.
View source version on accesswire.com:
https://www.accesswire.com/741403/NLS-Pharmaceutics-to-Present-at-the-35th-Annual-Roth-Conference
FAQ
When will NLS Pharmaceutics present at the Roth Conference?
What time is NLS Pharmaceutics' presentation at the Roth Conference?
Where is the 35th Annual Roth Conference taking place?
How can I access the webcast of NLS Pharmaceutics’ presentation?
What is the significance of the Roth Conference for NLS Pharmaceutics?
